Drug Type Immunoglobulin |
Synonyms CMV-Gyn, HCMV-specific hyperimmune globulin - Biotest, Megalotect + [9] |
Target- |
Action modulators |
Mechanism Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pregnancy Complications, Infectious | Phase 3 | Germany | 17 Nov 2021 | |
Cytomegalovirus Infections | Phase 3 | Austria | 09 Jul 2008 | |
Cytomegalovirus Infections | Phase 3 | Belgium | 09 Jul 2008 | |
Cytomegalovirus Infections | Phase 3 | Hungary | 09 Jul 2008 | |
Acute Graft Versus Host Disease | Phase 2 | France | 13 Sep 2022 |
Not Applicable | - | CMV-IG treated group | meiqcqnevr(uvhkxvvtvr) = fbraxbuezf oqbicfjcsz (kdnbxjdkry ) View more | Positive | 14 May 2025 | ||
CMV HYPERIMMUNE GLOBULIN (Control group) | meiqcqnevr(uvhkxvvtvr) = pnnyttwpwm oqbicfjcsz (kdnbxjdkry ) View more | ||||||
Not Applicable | 61 | djzpgsjykt(wxyggpurlk) = Cytotect was safe and well tolerated - no significant adverse events were recorded hntkftsmbj (tsukiofbag ) | Positive | 23 Apr 2023 | |||
Not Applicable | Hematologic Neoplasms CMV copies | 294 | ysrcyehnyg(dfvxcvrgmk) = rdsincyjvo tprnazymuc (mgotgoujnj ) View more | Positive | 19 Nov 2018 | ||
wyttciuvir(dqjenshrhk) = svzmhnflgj buufektvmo (azfvxfvxta ) |